Issuer/Instrument | Industry/ Rating |
% to Net Assets |
---|---|---|
Equity & Equity Related |
||
Reliance Industries Ltd. | Petroleum Products | 13.73 |
Infosys Ltd. | Software | 10.55 |
HDFC Bank Ltd. | Banks | 9.73 |
ICICI Bank Ltd. | Banks | 7.67 |
HDFC Ltd. | Finance | 6.54 |
Tata Consultancy Services Ltd. | Software | 5.85 |
Kotak Mahindra Bank Ltd. | Banks | 3.47 |
ITC Ltd. | Consumer Non Durables | 3.32 |
Larsen And Toubro Ltd. | Construction Project | 3.23 |
Axis Bank Ltd. | Banks | 3.14 |
Bajaj Finance Ltd. | Finance | 2.91 |
State Bank Of India | Banks | 2.86 |
Bharti Airtel Ltd | Telecom - Services | 2.76 |
Hindustan Unilever Ltd. | Consumer Non Durables | 2.76 |
Asian Paints Ltd. | Consumer Non Durables | 2.10 |
HCL Technologies Ltd. | Software | 1.91 |
Titan Company Ltd. | Consumer Durables | 1.60 |
Tata Steel Ltd. | Ferrous Metals | 1.57 |
Bajaj Finserv Ltd. | Insurance | 1.55 |
Maruti Suzuki India Limited | Auto | 1.52 |
Sun Pharmaceuticals Industries Ltd. | Pharmaceuticals | 1.49 |
Tech Mahindra Ltd. | Software | 1.41 |
Wipro Ltd. | Software | 1.32 |
Mahindra & Mahindra Ltd. | Auto | 1.17 |
Ultratech Cement Ltd. | Cement & Cement Products | 1.15 |
Power Grid Corporation Of India Ltd. | Power | 1.12 |
National Thermal Power Corporation Limited | Power | 0.97 |
Nestle India Ltd. | Consumer Non Durables | 0.94 |
IndusInd Bank Ltd. | Banks | 0.85 |
Dr Reddys Laboratories Ltd. | Pharmaceuticals | 0.79 |
Equity & Equity Related - Total | 99.98 | |
Net Current Assets/(Liabilities) | 0.02 | |
Grand Total | 100.00 |
Regular Plan
Fund Manager | Mr. Devender Singhal & Mr. Satish Dondapati* |
Benchmark | S&P BSE SENSEX TRI |
Allotment date | June 6, 2008 |
AAUM | Rs20.76 crs |
AUM | Rs21.61 crs |
Folio count | 1,387 |
Portfolio Turnover | 16.57% |
Tracking Error: | 0.10% |
Through Exchange: 1 Unit ,
Through AMC: 10000 Units,
Ideal Investment Horizon: 5 years and
above
Entry Load: Nil. (applicable for all plans)
Exit Load:
Nil (applicable for all plans)
Regular: 0.28%
Fund
Benchmark
* Investors should consult their financial advisers if in doubt about whether the product is suitable for them.